#CD40
📚 Efficacité et tolérance du dapirolizumab pegol, inhibiteur du ligand de CD40, dans le lupus systémique (PHOENYCS GO) : essai de phase 3 randomisé, en double aveugle, contrôlé contre placebo

💬 Résumé par le Docteur Benoit SUZON

🔗 drive.google.com/file/d/1KGpv...
November 19, 2026 at 2:01 PM
I've been watching $AMGN. Amgen reported Phase 3 Sjogren's win: CD40-CD40L blockade curbs germinal-centre B cell activation and autoantibody titres. Like refocusing a lens on pathogenic B cells. https://wsau.com/2026/11/11/amgens-experimental-sjogrens-drug-meets-late-stage-trial-goal/
November 17, 2026 at 2:05 PM
Nousiainen et al. in the Pietiäinen Lab at the University of Helsinki map neuroblastoma's immune landscape, finding sparse leukocytes (median 1.8% of cells) dominated by macrophages that co-express CD40, CSF1R and CD163, suggesting targets for macrophage-directed immunotherapy.
bioRxiv (Cancer Biology)
www.biorxiv.org
November 14, 2026 at 12:22 AM
Dual CD40/CD28 co-stimulation reprograms the solid-tumor microenvironment to unleash CAR-T and endogenous anti-tumor immunity https://www.biorxiv.org/content/10.64898/2026.11.08.762395v1
November 10, 2026 at 11:17 PM
Dual CD40/CD28 co-stimulation reprograms the solid-tumor microenvironment to unleash CAR-T and endogenous anti-tumor immunity #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.11.08.762395v1
November 11, 2026 at 2:01 AM
Dazodalibep, currently in phase 3 trials for treatment of Sjogren's, works by blocking this ligand

What is CD40

#ACR26 #KnowledgeBowl
November 8, 2026 at 6:14 PM
Had a great time presenting one of my ongoing research projects investigating CD40 agonism in the treatment of high-risk neuroblastoma at SITC2026 in sunny Arizona!🌵Now back to Wisconsin fall weather 😊🍂
November 8, 2026 at 5:51 PM
⭐ SLE - Dapirolizumab - Clowse Lancet

CD40 ligand inhibitor

#ACR26
November 8, 2026 at 1:00 PM
6) How does this happen? Reprogrammed cDC1-like cells interact with T cells through MHC class I and CD40 signaling to drive imgTLS formation.
November 4, 2026 at 4:46 PM
7) Spatial transcriptomics and imaging of imgTLSs revealed that DCs acquire conserved spatially restricted resident and migratory signaling programs in TLS-containing tumors. Both proximal and distal DC subsets promote rapid induction of lymphotoxin, TNFα, and CD40.
November 4, 2026 at 4:46 PM
'We found that ∼20% of bone marrow MKs express MHCII & co-stimulatory receptors CD80, CD86, CD40, and CD83. These MKs process and present antigen to activate T cells ex vivo in an MHC II-dependent manner. MK/T cell interactions induced TGF-β1 secretion and promoted induced #Treg differentiation'
MHC II-expressing bone marrow megakaryocytes are noncanonical antigen-presenting cells and activate CD4+ T cells ex vivo
Camacho et al. show a subset of megakaryocytes, best known as platelet-producing cells, also have immune functions. MHC II-expressing megakaryocytes process antigen ex vivo, activate CD4+ T cells, and...
www.cell.com
November 4, 2026 at 9:30 AM
CD40 ligand and IFN-γ induce proinflammatory activity and microglia-mediated neurodegeneration in human stem cell models https://www.biorxiv.org/content/10.64898/2026.10.28.749776v1
November 3, 2026 at 2:18 PM
CD40 ligand and IFN-γ induce proinflammatory activity and microglia-mediated neurodegeneration in human stem cell models #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.10.28.749776v1
November 3, 2026 at 5:02 PM
CD40 ligand and IFN-γ induce proinflammatory activity and microglia-mediated neurodegeneration in human stem cell models https://www.biorxiv.org/content/10.64898/2026.10.28.749776v1
November 3, 2026 at 2:18 PM
Check out the October FOCIS editors' choice highlights in Science Immunology🔬

Pairing up to decode recognition: zurl.co/VdA5U
Old dog, new tricks: Astrocytes use the CD40 pathway to propagate neuroinflammation: zurl.co/YphFe

@science.org #FOCIS
Old dog with new tricks: SARS-CoV-2 variant–specific B cells complement imprinted memory
Both memory and de novo antibody clones neutralize SARS-CoV-2 variants, but with distinct origins and targets.
www.science.org
October 30, 2026 at 2:53 PM
Submissions are still open for our CD40 turns 40 Special Collection, exploring four decades of CD40 biology and its impact on immunotherapy across cancer, autoimmunity, and more 🧬

Learn more about submitting here: vist.ly/5pmz9

#Immunology #Immunotherapy
Call for Papers
Immunotherapy Advances publishes scientifically rigorous open access research relating to manipulations of the immune system for the benefit of human and a
academic.oup.com
October 23, 2026 at 10:59 AM
Read the Phase 1 Study: CD40 Agonist, Sotigalimab, in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly-diagnosed DIPG (NCT03389802, PBTC-051), in Clinical Cancer Research. buff.ly/QC5Pl2x
October 18, 2026 at 7:32 PM
B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity
B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity
CD40-stimulated B cells drive infiltration, organization, and cytotoxic function of CD8+ T cells in triple-negative breast tumors, advancing our understanding of how B cell interactions with CD8+ T cells can influence anti-tumor responses.
dlvr.it
October 13, 2026 at 11:23 PM
CD40 engagement and proinflammatory cytokines promote lipid droplet accumulation in astrocytes and subsequent antigen presentation, boosting pathogenic CD4+ T cell responses
Spotlight @cp-immunity.bsky.social
www.cell.com/immunity/ful...
www.nature.com/articles/s41...
October 13, 2026 at 4:39 PM
Hi all, next serminar will be given by Dr. Yolanda Carrasco, from Centro Nacional de Biotechnologica in Spain:

Deciphering the CD40-mediated immune synapse in B lymphocytes: molecular mechanisms and mechanobiology features

see you on October 29th at 16:30 CEST (2:30 PM UTC)
October 12, 2026 at 7:01 PM
Giulia Golinelli, Ting-Jia Fan, Khatuna Gabunia, Wesley V Wilson, Charles-Antoine Assenmacher, He N Xu, Diego Gonzalves, Sofia Castelli, Jordan Reff, David Mai, Omar Johnson, Zachary Ferraro, Aasha Gupta, Mansi Deshmukh, Deeksha Muthumani, Decheng Song, Daniel Martinez, Enrico Radaelli, et al.
Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models
CONCLUSIONS: These findings set the stage for future clinical applications of CAR T cells in combination with CD40 agonists for the treatment of challenging solid tumors.
linkinghub.elsevier.com
October 9, 2026 at 4:00 AM